Andrx Granted FDA Tentative Approval For Generic Nolvadex.

Business Editors & Health/Medical Writers

Andrx Corporation (Nasdaq:ADRX) today announced that the United States Food and Drug Administration (FDA) has tentatively approved the marketing of its Abbreviated New Drug Application (ANDA) for 10 mg and 20 mg tamoxifen citrate tablets USP, which are bioequivalent to Nolvadex(R). Marketed by Astrazeneca Pharmaceuticals LP, Nolvadex is used in the treatment of breast cancer. Nolvadex, and a licensed generic version thereof, are presently being marketed, and had combined 2001 product sales of approximately $515 million.

Andrx Chief Executive Officer, Richard J. Lane, commented: "This is the second of our generic products to receive FDA tentative approval in the past two weeks. We are pleased that our products are continuing to work their way through the regulatory system, in anticipation of their launch."

A tentative approval indicates that FDA has made an initial determination that the application for a generic drug satisfies the substantive requirements for approval, subject to the expiration of all statutorily imposed periods during which approval cannot be granted. Final marketing approval is required for the applicant to market the generic drug. The earliest Andrx's generic version of Nolvadex could receive FDA final marketing approval is February 20, 2003, as U.S. patent No. 4,536,516, which covers Nolvadex and which includes a pediatric extension, is scheduled to expire on that date.

About Andrx

Andrx Corporation is a specialty pharmaceutical company engaged in the commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies. Andrx also distributes generic pharmaceutical products manufactured by third parties.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, there can be no assurance as to when or whether the Andrx ANDA for Nolvadex will receive final marketing approval from the FDA, and words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com